Trial reportNeuromodulation : journal of the International Neuromodulation Society2025
Transcutaneous Cervical Vagus Nerve Stimulation Improves Speech Comprehension in Noise: A Crossover, Placebo-Controlled Study.
Trial report in Neuromodulation : journal of the International Neuromodulation Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
backgroundSpeech comprehension in noisy environments remains a significant challenge, even among individuals with clinically normal hearing and users of hearing aids and cochlear implants. Although conventional assistive hearing devices address limitations in the auditory periphery, they do not directly enhance the brain's capacity to segregate speech from background noise. Because tonic vagus nerve stimulation (VNS) has shown potential for rapidly improving central sensory processing, this study investigated whether tonic transcutaneous cervical VNS (tcVNS) can enhance speech-in-noise intelligibility. MATERIALS AND
methodsTwo cohorts of older human adults (aged 60-84 years) participated in a placebo-controlled, crossover study. Participants completed speech-in-noise assessments using either QuickSIN or AzBio sentences while receiving tonic tcVNS to the neck, or placebo stimulation to the neck-shoulder junction. Speech-in-noise performance was assessed by measuring participants' accuracy in repeating sentences presented at varying signal-to-noise ratios (SNR) within background babble.
resultsTonic tcVNS improved speech-in-noise intelligibility compared with placebo. At the group level, the SNR threshold for 50% speech intelligibility (SNR-50) improved by 0.76 dB in QuickSIN (p = 0.016) and by 0.38 dB in AzBio (p = 0.045). For individual participants, 50% showed improvements that met a minimum clinically important difference (MCID) of 1 dB. Tonic tcVNS evoked progressively greater improvements as SNR increased in QuickSIN (p = 0.021) and AzBio (p = 0.00023), with the largest gains at SNRs >0 dB. In 55% of participants, tcVNS improved intelligibility beyond an MCID benchmark of 4.9% at 5 dB SNR. Although the magnitude of tcVNS-evoked improvements was inversely related to baseline speech-in-noise impairment (p = 0.028), with the individuals having the most impaired speech-in-noise intelligibility showing the largest gains, it did not correlate with hearing loss severity (p = 0.97) or age (p = 0.88).
conclusionsOur findings indicate that tonic tcVNS can evoke immediate and clinically meaningful enhancements in speech-in-noise comprehension. This suggests tcVNS may complement conventional assistive hearing technologies and inform novel therapies for sensory processing disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.